Wang Qi Zhao, Lv Ying Hui, Diao Yong, Xu Ruian
Institute of Molecular Medicine, Huaqiao University, China 362021.
Curr Pharm Des. 2008;14(13):1327-40. doi: 10.2174/138161208799316357.
RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
RNA干扰(RNAi)是一种依赖双链RNA的转录后基因沉默过程,主要发生在细胞的mRNA加工小体(P小体)中。基于对靶基因的高度特异性和高效沉默,它已成为遗传分析和分子治疗中最强大且应用最广泛的基因策略。在体外和体内实现有效RNAi的关键挑战在于将其递送至所需器官和靶细胞。RNAi递送系统可以是非病毒载体或病毒载体。作为治疗工具,RNAi的主要候选者是基于病毒的载体,包括逆转录病毒、腺病毒、腺相关病毒(AAV)、慢病毒和单纯疱疹病毒1型(HSV-1)。RNAi在治疗多种人类疾病,包括遗传疾病、传染病和癌症方面具有很高的临床应用潜力。本文综述了基于质粒或病毒的可诱导、组织特异性、杂交、溶瘤和高通量RNAi载体的设计,并讨论了它们的特异性、效率和安全性。